These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 28160873)
1. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Valter I; Fitzpatrick LA; Riis BJ; Christiansen C; Bilezikian JP; Black D Mayo Clin Proc; 2017 Feb; 92(2):200-210. PubMed ID: 28160873 [TBL] [Abstract][Full Text] [Related]
2. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. Bone HG; Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Fitzpatrick LA; Mitlak B; Papapoulos S; Rizzoli R; Dore RK; Bilezikian JP; Saag KG J Clin Endocrinol Metab; 2018 Aug; 103(8):2949-2957. PubMed ID: 29800372 [TBL] [Abstract][Full Text] [Related]
3. Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial. Watts NB; Dore RK; Baim S; Mitlak B; Hattersley G; Wang Y; Rozental TD; LeBoff MS Osteoporos Int; 2021 Jan; 32(1):55-61. PubMed ID: 32935170 [TBL] [Abstract][Full Text] [Related]
4. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis. Leder BZ; Mitlak B; Hu MY; Hattersley G; Bockman RS J Clin Endocrinol Metab; 2020 Mar; 105(3):938-43. PubMed ID: 31674644 [TBL] [Abstract][Full Text] [Related]
5. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C; JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157 [TBL] [Abstract][Full Text] [Related]
6. Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial. Leder BZ; Zapalowski C; Hu MY; Hattersley G; Lane NE; Singer AJ; Dore RK J Bone Miner Res; 2019 Dec; 34(12):2213-2219. PubMed ID: 31411768 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States. Le QA; Hay JW; Becker R; Wang Y Ann Pharmacother; 2019 Feb; 53(2):134-143. PubMed ID: 30160186 [TBL] [Abstract][Full Text] [Related]
8. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. Miller PD; Bilezikian JP; Fitzpatrick LA; Mitlak B; McCloskey EV; Cosman F; Bone HG Curr Med Res Opin; 2020 Nov; 36(11):1861-1872. PubMed ID: 32969719 [TBL] [Abstract][Full Text] [Related]
9. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture. Hiligsmann M; Williams SA; Fitzpatrick LA; Silverman SS; Weiss R; Reginster JY Semin Arthritis Rheum; 2019 Oct; 49(2):184-196. PubMed ID: 30737062 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective. Hiligsmann M; Williams SA; Fitzpatrick LA; Silverman SS; Weiss R; Reginster JY Semin Arthritis Rheum; 2020 Jun; 50(3):394-400. PubMed ID: 32160943 [TBL] [Abstract][Full Text] [Related]
12. Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis. Reginster JY; Al Daghri N; Kaufman JM; Bruyère O Expert Opin Pharmacother; 2018 Feb; 19(2):159-161. PubMed ID: 29251010 [TBL] [Abstract][Full Text] [Related]
13. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. McClung MR; Harvey NC; Fitzpatrick LA; Miller PD; Hattersley G; Wang Y; Cosman F Menopause; 2018 Jul; 25(7):767-771. PubMed ID: 29462094 [TBL] [Abstract][Full Text] [Related]
14. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial. Bilezikian JP; Hattersley G; Fitzpatrick LA; Harris AG; Shevroja E; Banks K; Leder BZ; Zanchetta JR; Hans D Osteoporos Int; 2018 Feb; 29(2):323-328. PubMed ID: 29167971 [TBL] [Abstract][Full Text] [Related]
15. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS; Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222 [TBL] [Abstract][Full Text] [Related]
16. Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture. Saag KG; Williams SA; Wang Y; Weiss RJ; Cauley JA Clin Ther; 2020 Jun; 42(6):1099-1107.e1. PubMed ID: 32513495 [TBL] [Abstract][Full Text] [Related]
17. Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend. Greenspan SL; Fitzpatrick LA; Mitlak B; Wang Y; Harvey NC; Deal C; Cosman F; McClung M Menopause; 2020 Oct; 27(10):1137-1142. PubMed ID: 32665529 [TBL] [Abstract][Full Text] [Related]
18. Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual-Energy X-Ray Absorptiometry (DXA). Winzenrieth R; Kostenuik P; Boxberger J; Wang Y; Humbert L JBMR Plus; 2022 Apr; 6(4):e10612. PubMed ID: 35434451 [TBL] [Abstract][Full Text] [Related]
19. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Recker RR; Kendler D; Recknor CP; Rooney TW; Lewiecki EM; Utian WH; Cauley JA; Lorraine J; Qu Y; Kulkarni PM; Gaich CL; Wong M; Plouffe L; Stock JL Bone; 2007 Apr; 40(4):843-51. PubMed ID: 17182297 [TBL] [Abstract][Full Text] [Related]
20. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. Bauer DC; Garnero P; Hochberg MC; Santora A; Delmas P; Ewing SK; Black DM; J Bone Miner Res; 2006 Feb; 21(2):292-9. PubMed ID: 16418785 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]